We've updated our story after media and analyst calls. The gist:
- data are good but didn't hit bull expectations
- dosing Qs remain, especially in the obesity/overweight cohort w/o T2D
- tolerability outside of the dose escalation arms is pretty unknown
- data are good but didn't hit bull expectations
- dosing Qs remain, especially in the obesity/overweight cohort w/o T2D
- tolerability outside of the dose escalation arms is pretty unknown
Reposted from
Max Bayer
Amgen's MariTide data are here:
- 20% weight loss at 52 wks for patients obese/overweight
- 17% weight loss at 52 weeks for patients obese/overweight + T2D
- in DE arms (~100 out of 600 ph. 2 patients) GI dropout rate was less than 8%
endpts.com/amgens-once-...
- 20% weight loss at 52 wks for patients obese/overweight
- 17% weight loss at 52 weeks for patients obese/overweight + T2D
- in DE arms (~100 out of 600 ph. 2 patients) GI dropout rate was less than 8%
endpts.com/amgens-once-...
Comments